Prev Chronic Dis by Jones, Miranda R et al.
PREVENTING  CHRONIC  DISEASE
P U B L I C  H E A L T H  R E S E A R C H ,  P R A C T I C E ,  A N D  P O L I C Y 





Cigarette Smoking and Prostate Cancer





Suggested  citation  for  this  article:  Jones MR,  Joshu CE,
Kanarek N, Navas-Acien A, Richardson KA, Platz EA. Cigarette
Smoking  and  Prostate  Cancer  Mortality  in  Four  US  States,





In the United States, prostate cancer mortality rates have declined
in recent decades. Cigarette smoking, a risk factor for prostate can-
cer death, has also declined. It is unknown whether declines in
smoking prevalence produced detectable declines in prostate can-
cer mortality. We examined state prostate cancer mortality rates in
relation to changes in cigarette smoking.
Methods
We studied men aged 35 years or older from California, Kentucky,
Maryland, and Utah. Data on state smoking prevalence were ob-
tained from the Behavioral Risk Factor Surveillance System. Mor-
tality rates for prostate cancer and external causes (control condi-
tion) were obtained from the Centers for Disease Control and Pre-
vention’s Wide-Ranging Online Data for Epidemiologic Research.
The average annual percentage change from 1999 through 2010
was estimated using joinpoint analysis.
Results
From 1999 through 2010, smoking in California declined by 3.5%
per year (−4.4% to −2.5%), and prostate cancer mortality rates de-
clined by 2.5% per year (−2.9% to −2.2%). In Kentucky, smoking
declined by 3.0% per year (−4.0% to −1.9%) and prostate cancer
mortality rates declined by 3.5% per year (−4.3% to −2.7%). In
Maryland, smoking declined by 3.0% per year (−7.0% to 1.2%),
and prostate  cancer  mortality  rates  declined by 3.5% per  year
(−4.1% to −3.0%).In Utah, smoking declined by 3.5% per year
(−5.6% to −1.3%) and prostate cancer mortality rates declined by
2.1% per year (−3.8% to −0.4%). No corresponding patterns were
observed for external causes of death.
Conclusion
Declines in prostate cancer mortality rates appear to parallel de-
clines in smoking prevalence at the population level. This study
suggests that declines in prostate cancer mortality rates may be a
beneficial effect of reduced smoking in the population.
Introduction
Reductions in the prevalence of smoking subsequent to imple-
mentation of tobacco control policies in the United States and oth-
er countries are associated with population-level reductions in in-
cidence and mortality from many smoking-associated diseases, in-
cluding cardiovascular disease, respiratory diseases, and lung can-
cer (1). In the 2014 Surgeon General’s report, the list of diseases
causally associated with smoking was expanded to include pro-
state cancer (1).
In the United States, prostate cancer mortality rates have declined
since the 1990s (2). These declines are due, at least in part, to the
combination of prostate specific antigen (PSA)-based prostate can-
cer screening and better treatment of men diagnosed with prostate
cancer  and  men  who  progress  to  metastatic  disease  (3–6).
However, these factors do not entirely explain the decline (3,7).
Current  cigarette  smoking,  rather  than  past  or  cumulative
smoking, is a risk factor for prostate cancer with aggressive patho-
logic characteristics and increased risk of recurrence and progres-
sion among men who have prostate cancer, and for prostate can-
cer mortality (8). Therefore, the national decline in smoking could
have contributed to the decline in prostate cancer mortality rates.
We conducted an ecological study to investigate state-level pro-
state  cancer  mortality  rates  in  relation to  changes  in  cigarette
smoking among white and black men in 4 US states — California,
Kentucky, Maryland, and Utah — during the recent era of declin-
ing prostate cancer mortality rates. The 4 states in our study were
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selected to provide data on a range of population smoking behavi-
ors. As of 2010, Kentucky had the highest prevalence of current
smoking among adults in the United States (24.8%), Utah had the
lowest prevalence (9.1%), and California (12.1%) and Maryland
(15.2%) each had an intermediate prevalence (9). We conducted
this study to determine whether population-level tobacco control
efforts produced detectable declines in prostate cancer mortality
rates in the population.
Methods
Study population
We studied men aged 35 years or older, irrespective of race/ethni-
city, who resided in 4 US states from 1999 through 2010: Califor-
nia, Kentucky, Maryland, and Utah. We also examined data for
non-Hispanic white (white) and non-Hispanic black (black) men
aged 35 years or older in the 3 states with available data (Califor-
nia, Kentucky, Maryland). Men aged 35 years or older were selec-
ted to capture data on the majority of prostate cancer deaths in the
4 states.
Prevalence of smoking
Data on the state-specific prevalence of current cigarette smoking
for men aged 35 years or older from 1999 through 2010 were ob-
tained  from  the  Behavioral  Risk  Factor  Surveillance  System
(BRFSS). The BRFSS is a cross-sectional survey conducted by the
Centers  for  Disease  Control  and  Prevention  (CDC)  and  state
health departments to obtain state-level estimates of the preval-
ence of certain health behaviors, diseases, and use of preventive
services among noninstitutionalized US adults  (10).  Response
rates for BRFSS 1999–2010 ranged from 35.4% to 58.1% in Cali-
fornia, 53.1% to 67.0% in Kentucky, 31.4% to 54.6% in Mary-
land, and 63.2% to70.6% in Utah (10). To determine current cigar-
ette smoking status, participants were asked, “Have you smoked at
least 100 cigarettes in your entire life?” and “Do you now smoke
cigarettes every day, some days, or not at all?” Participants were
classified as current smokers if they reported smoking at least 100
cigarettes during their lifetime and currently smoked at least some
days.
Mortality outcomes
Annual mortality rates for men aged 35 years or older from 1999
through 2010 were obtained from CDC’s Wide-Ranging Online
Data for Epidemiologic Research (CDC WONDER) system (11).
CDC WONDER compiles nationwide death certificate data from
the National Center for Health Statistics (NCHS). The NCHS cap-
tures data on more than 99% of deaths in the United States (12).
Prostate cancer deaths were classified according to the Internation-
al Classification of Diseases, Tenth Revision (ICD-10), code C61.
As a control condition, we examined mortality rates from external
causes  (eg,  accidents,  homicides,  suicides;  ICD-10  codes
V01–Y89),  which  are  not  expected  to  be  related  to  trends  in
smoking.
Statistical analyses
For each state, the prevalence of current smoking for men aged 35
years or older was estimated for each year (1999–2010) by using
the survey package (version 3.29) in R statistical software (ver-
sion 3.0.2) (The R Foundation) to account for BRFSS sampling
weights. State-specific mortality rates for prostate cancer and ex-
ternal causes for men aged 35 years or older were age-standard-
ized to the 2000 US standard million population and expressed per
100,000 persons.  We estimated the average annual percentage
change (AAPC) from 1999 through 2010 and the corresponding
95% confidence intervals (CIs) for current smoking, prostate can-
cer mortality rates, and mortality from external causes by join-
point analysis (Joinpoint Regression Program, version 4.1.0 [Na-
tional Cancer Institute] (http://surveillance.cancer.gov/joinpoint/
)(13) and compared the observed trends in smoking and mortality
outcomes in each state. A maximum of 2 joinpoints, correspond-
ing to 3 segments, were allowed for each analysis. Years for join-
points were not prespecified. For each state, the locations of the
best fitting joinpoints (if any) that indicated a significant change in
the slope in that analysis were retained in the final model. Ana-
lyses were conducted for all men irrespective of race/ethnicity in
California, Kentucky, Maryland, and Utah. We also conducted
analyses separately for white and black men in California, Ken-
tucky, and Maryland.
Results
In 1999, the prevalence of smoking among men aged 35 years or
older ranged from 14.8% in Utah to 31.7% in Kentucky (Table 1).
By 2010, the smoking prevalence among men had declined in all 4
states (Table 1) (Figure). In California, Kentucky, and Maryland
(states with available data on both white and black men), the pre-
valence of smoking was higher among black men than among
white men. In 1999, age-adjusted prostate cancer mortality rates
per 100,000 for men aged 35 years or older was 56.1 in California,
65.7 in Kentucky, 68.4 in Maryland, and 64.2 in Utah (Table 1).
Similar to the trend observed in smoking, prostate cancer mortal-
ity rates also declined in all 4 states by 2010 (Table 1) (Figure).
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Figure. Trends in cigarette smoking and prostate cancer mortality rates among
men aged 35 years or older, Behavioral Risk Factor Surveillance System and
CDC WONDER, 1999–2010. Solid lines represent trends in the weighted
prevalence of cigarette smoking among men aged 35 years or older,  and
dashed lines represent trends in age-adjusted prostate cancer mortality rates
for  men aged 35 years or  older.  Abbreviation:  CDC WONDER, Centers for
Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic
Research.
 
In Maryland, which had the highest prostate cancer mortality rates
in 1999, the prevalence of smoking among men aged 35 years or
older from 1999 through 2010 declined nonsignificantly by 3.0%
per year (95% CI, −7.0% to 1.2%), and prostate cancer mortality
rates declined by 3.5% per year (95% CI, −4.1% to −3.0%) (Table
2). In Kentucky, which had the second highest prostate cancer
mortality rates, the prevalence of smoking declined by 3.0% per
year (95% CI, −4.0% to −1.9%), and prostate cancer mortality
rates declined by 3.5% per year (95% CI,  −4.3% to −2.7%) (Ta-
ble 2) for the same period. In California, which had the lowest
prostate cancer mortality rates in 1999, the prevalence of smoking
during this period declined by 3.5% per year (95% CI, −4.4% to
−2.5%), and prostate cancer mortality rates declined by 2.5% per
year  (95%  CI,  −2.9%  to  −2.2%).  In  Utah,  the  prevalence  of
smoking declined by 3.5% per year (95% CI, −5.6% to −1.3%)
from 1999 through 2010, and mortality rates from prostate cancer
declined by 2.1% per year (95% CI, −3.8% to −0.4%). During this
period, mortality rates from external causes, which are not expec-
ted  to  be  related  to  population changes  in  smoking,  remained
stable in California, Maryland, and Utah and increased signific-
antly in Kentucky (Table 2).
The prevalence of smoking among white men in 1999 ranged from
14.4% in Utah to 31.9% in Kentucky (Table 1). In Kentucky, the
prevalence of smoking among white men declined by 3.4% per
year (95% CI, −4.7% to −2.1%), and prostate cancer mortality
rates  similarly  declined  by  3.4% per  year  (95% CI,  −4.4% to
−2.4%) (Table 2) from 1999 through 2010. Among white men in
Maryland, both smoking prevalence and prostate cancer mortality
rates decreased from 1999 through 2010 (AAPC:  −3.9%; 95% CI,
−5.2% to −2.7% per year for smoking and −3.7%, 95% CI; −4.6%
to −2.9% per year for prostate cancer mortality rates). The de-
clines in prostate cancer mortality rates among white men were
smaller  in  California  and  Utah  compared  with  Kentucky  and
Maryland (Table 2). Among white men in California, prostate can-
cer  mortality  declined  by  2.4%  per  year  (95%  CI,  −2.8%  to
−1.9%) and cigarette smoking declined by 4.0% per year (95% CI,
−5.2% to −2.9%) from 1999 through 2010. In Utah, prostate can-
cer mortality rates declined by 1.8% per year (95% CI, −3.5% to
0),  and cigarette smoking declined by 3.8% per year (95% CI,
−5.9% to −1.7%).  During this  period,  mortality  from external
causes among white men increased significantly in all states (Ta-
ble 2).
Although the prevalence of smoking declined significantly among
white men in all 4 states, smoking prevalence among black men
declined significantly only in Maryland (Table 2). In Maryland,
both smoking and prostate cancer mortality rates significantly de-
creased  among  black  men  from 1999  through  2010  (AAPCs:
−5.0%; 95% CI, −7.4% to −2.6% per year for smoking and −4.0%;
95% CI, −5.4% to −2.6% per year for prostate cancer mortality
rates). Among black men in California, the prevalence of smoking
decreased nonsignificantly, by 1.8% per year (95% CI, −4.9% to
1.4%), and mortality from prostate cancer significantly decreased
by 2.7% per year (95% CI, −4.1% to −1.2%). In Kentucky, there
were no significant changes in the prevalence of smoking or pro-
state cancer mortality rates for black men (Table 2). In Maryland
and Kentucky, black men experienced a significant decline in mor-
tality from external causes, and in California, there was a nonsig-
nificant decrease in mortality from external causes among black
men (Table 2).
Discussion
Using state-level data on smoking behaviors and mortality out-
comes, we observed similar declines in the prevalence of smoking
and prostate cancer mortality rates among adult men in 4 US states
from 1999 through 2010. We also observed greater declines in
prostate cancer mortality rates in Kentucky and Maryland during
that  period,  with  those  states  having  a  higher  prevalence  of
smoking in 1999 compared with California and Utah. We studied
concurrent trends rather than lagged trends, because epidemiolo-
gic studies indicate that current smoking has important implica-
tions for fatal prostate cancer (1). Studies are needed to further
evaluate the impact of reductions in smoking in preventing pro-
state cancer deaths.
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Decreases in prostate cancer mortality rates observed at the popu-
lation level may be due, in part, to decreases in smoking. A 2009
review of prospective epidemiologic studies concluded that cur-
rent cigarette smoking was associated with a 30% increased risk
for fatal prostate cancer compared with nonsmokers (8). When re-
cent smoking was considered (ie, smoking status within 10 years
before cancer death), there was a twofold increase in risk for fatal
prostate cancer in men who currently smoked or quit within the
past 10 years compared with never smokers (8,14,15).
Smoking status at the time of diagnosis is associated with risk for
death from prostate cancer (16,17). In the Health Professionals
Follow-Up Study (5,366 men diagnosed with prostate cancer from
1986 through 2006), men who reported smoking at the time of dia-
gnosis had increased risk for prostate cancer death (hazard ratio,
1.82; 95% CI, 1.03–3.20) compared with never smokers (17). For
prostate cancer mortality, former smokers within 10 years of quit-
ting in the Physicians Health Study (19,705 male physicians re-
cruited from 1982 through 1984) had reduced risk for prostate
cancer death compared with current smokers, and after 30 years of
cessation, the risk for death from prostate cancer was similar to
never smokers (18). At the population level, shifts in prostate can-
cer mortality rates could be attributed to such changes in smoking
behaviors altering the risk for fatal prostate cancer throughout the
population.
Although previous studies described the impact of changes in pro-
state cancer screening or treatment on changes in prostate cancer
mortality rates, these changes did not completely explain reduc-
tions in prostate cancer mortality rates (3,5). Rates of surgery and
radiation therapy to treat localized prostate cancer increased in the
United States from the 1980s through the mid-to-late 1990s (3).
Information on trends in the use of prostate cancer treatment in the
4 states during this period was unavailable; however, estimates are
that changes in treatment (radical prostatectomy, radiation therapy,
and androgen deprivation) in the United States could explain 16%
to 23% of the decline in prostate cancer mortality rates that oc-
curred from 1991 through 2005 (3). PSA screening began in the
United States in the late 1980s and early 1990s and stabilized by
the mid-1990s (19). Information on prostate cancer screening was
available for men aged 40 years or older in the BRFSS for survey
years 2001, 2002, 2004, 2006, 2008, and 2010. Based on these
data, the percentage of men who reported being screened for pro-
state cancer by PSA test or digital-rectal examination remained
stable from 2001 through 2010 in Maryland and Kentucky and de-
creased in California and Utah (AAPCs: −0.8%; 95% CI, −1.8% to
0.1% per year in Maryland; −1.4%; 95% CI, −2.2% to −0.6% per
year in California; 1.7%; 95% CI, −0.5% to 4.0% per year in Ken-
tucky; −0.6%; 95% CI, −1.1% to −0.1% per year in Utah). These
data suggest that increased PSA screening in these states does not
fully explain our findings, although we cannot rule out possible
time-delayed effects of earlier (pre-2000) PSA screening and pro-
state cancer treatment.
We found greater declines in both smoking and prostate cancer
mortality rates among black men compared with white men in
Maryland, which was the only state in which we observed a signi-
ficant change in the prevalence of smoking among black men.
Compared with white men, black men have a higher incidence of
prostate cancer, are more commonly diagnosed with late-stage and
high-grade tumors, and have a higher risk for fatal prostate cancer
(20). In the United States, black men are also less likely to receive
PSA testing (21) or definitive therapy (radical prostatectomy or ra-
diation therapy) than white men (22). Given the lower rates of pro-
state cancer screening and treatment among black men than white
men, our finding of a greater decline in prostate cancer mortality
rates among black men than white men in Maryland could not be
attributed to racial differences in use of these services.
Despite its low smoking prevalence, Utah had high prostate can-
cer mortality rates compared with other states in our study. The
low prevalence of smoking in Utah is largely due to the state’s re-
ligious composition. Members of the Church of Jesus Christ of
Latter-Day Saints (LDS), who make up about 70% of Utah’s pop-
ulation (23), practice tobacco abstinence. In Utah in 1996, only
9.2% of  LDS men  smoked,  whereas  24.5% of  non-LDS men
smoked, a prevalence that exceeded the national average (24).We
speculate that the higher rate of prostate cancer mortality in Utah
despite an overall low smoking prevalence could be the result of
prostate cancer deaths occurring among non-LDS men who are
more likely to smoke. However, we do not have information to
confirm our speculation.
We used representative data on smoking for men in 4 US states in
conjunction with mortality data to examine state-level trends in
prostate cancer mortality rates in relation to changes in cigarette
use in the population. By examining states with different smoking
prevalence and mortality rates we were able to demonstrate that
the  similarities  between  prostate  cancer  mortality  rates  and
smoking trends occurred in different populations. The use of mor-
tality from external causes as a control condition allowed for fur-
ther comparison of time trends that would not be expected to be
influenced by population changes in smoking. We observed no
changes in the rates of mortality from external causes over the
time period except for an increased trend in Kentucky, which may
reflect an increase in the rate of suicide in Kentucky during this
time (25).
Our study was an ecological analysis. With this design, we were
unable to conclude a causal association, only that the 2 time trends
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were similar. However, assessing a causal association was not our
goal. Instead, we wanted to determine whether declines in the pre-
valence of  cigarette  smoking,  a  risk factor  for  prostate  cancer
death, paralleled declines in prostate cancer mortality rates in the
population. This study was limited to men in 4 US states, which
we selected to provide a range of prostate cancer mortality rates,
smoking patterns, racial demographics, and geographic regions;
future research is needed to confirm our findings in additional
states. The use of state-level data for prostate cancer mortality out-
comes does not provide clinical or pathologic information about
prostate cancer diagnosis; therefore, we were unable to examine
trends in case-fatality rates according to disease characteristics
(eg,  disease severity  at  diagnosis).  Last,  because of  our  study
design we were unable to account for prostate cancer screening
and treatment or for possible risk factors (eg, obesity, physical in-
activity) and protective factors (eg, statin use) for fatal prostate
cancer (26,27). These factors may contribute differences in find-
ings for black men compared with white men in this study.
In the past decade, the prevalence of obesity increased signific-
antly among US adults (28), and levels of physical activity re-
mained stable (29). Thus, the observed decreases in prostate can-
cer mortality rates occurred despite the upward trend in obesity.
Following the 2001 publication of the National Cholesterol Educa-
tion Program Third Adult Treatment Panel guidelines, which re-
commended statin use for patients with high levels of low-density
lipoprotein (LDL) cholesterol, the percentage of US adults with
high levels of  LDL cholesterol who reported statin use nearly
doubled (from 19.6% in 1999–2000 to 35.9% in 2003–2004) (30).
In our study, we did not find a significant change in the trend for
prostate cancer mortality rates after 2001 (P value for any join-
points > .05 for all states), and the rates for prostate cancer mortal-
ity declined gradually over the period, consistent with a gradual
change in risk factors as opposed to the sharp decrease we would
expect following the sudden increase of statin use.
From 1999 through 2010, decreasing prostate cancer mortality
rates were consistent with  a reduction in cigarette smoking at the
population level. The association between prostate cancer mortal-
ity rates and smoking prevalence was observed in states with vari-
ous smoking behaviors and prostate cancer mortality rates. Addi-
tionally, the lack of change in smoking prevalence among black
men in Kentucky was related to unchanged prostate cancer mortal-
ity rates in that state. These findings support the need for targeted
smoking cessation efforts,  which could reduce prostate cancer
mortality rates in this population burdened by both higher rates of
prostate cancer and an elevated prevalence of cigarette smoking.
Finally,  these  findings  support  population-wide  reductions  in
smoking as a potential strategy to reduce deaths from prostate can-
cer.
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Tables
Table 1. Smoking and Mortality Rates for Prostate Cancer and External Causes Among Men Aged 35 Years or Older in 4 States,
BRFSS, 1999–2010 and CDC WONDER, 1999–2010
Characteristic California Kentucky Maryland Utaha
Overall
Numbera 9,009,384 1,114,787 1,444,239 553,693
Current smokers, %b
1999 19.9 31.7 20.9 14.8
2010 12.8 23.7 15.6 9.4
Prostate cancer mortality rates
Number of deathsc 36,318 4,883 6,539 2,242
1999, per 100,000 56.1 65.7 68.4 64.2
2010, per 100,000 41.4 42.3 43.6 51.4
Death from external causes
Numberc 88,473 16,569 16,405 6,753
1999, per 100,000 89.7 123.6 103.1 115.8
2010, per 100,000 90.0 159.4 97.0 124.2
Non-Hispanic White Men
Numbera 4,603,645 1,006,663 905,567 473,530
Current smokers, %b
1999 19.7 31.9 19.0 14.4
2010 11.4 22.6 14.0 8.9
Prostate cancer mortality rates
Numberc 26,104 4,350 4,156 2,131
1999, per 100,000 57.8 63.0 56.8 63.3
2010, per 100,000 43.6 41.2 33.9 52.5
Death from external causes
Numberc 57,594 15,575 10,580 6,086
1999, per 100,000 96.6 125.2 92.4 112.8
2010, per 100,000 110.5 168.2 101.5 127.7
Non-Hispanic Black Men
Numbera 550,147 73,278 371,891 5,755
Abbreviations: BRFSS, Behavioral Risk Factor Surveillance System; CDC WONDER, Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epi-
demiologic Research.
a Men aged 35 or older in 2010. The number for overall does not equal the total for whites and blacks because that number includes all men in the state, irrespect-
ive of race/ethnicity.
b Values for smoking status are weighted percentages (incorporating sampling weights) for 1999 and 2010.
c Total deaths from select causes from 1999 to 2010
d Insufficient data for current smoking, prostate cancer mortality rates, and mortality from external causes for black men in Utah (≤20 participants for current
smoking or ≤20 deaths for mortality outcomes for all years).
(continued on next page)
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(continued)
Table 1. Smoking and Mortality Rates for Prostate Cancer and External Causes Among Men Aged 35 Years or Older in 4 States,
BRFSS, 1999–2010 and CDC WONDER, 1999–2010
Characteristic California Kentucky Maryland Utaha
Current smokers, % b
1999 27.3 26.5 30.2  —d
2010 19.5 35.9 21.8  —d
Prostate cancer mortality rates
Numberc 3,970 502 2,259  —d
1999, per 100,000 125.0 109.5 137.6  —d
2010, per 100,000 86.5 70.5 88.0 —d
Death from external causes
Numberc 7,430 791 5,139 —d
1999, per 100,000 117.4 113.1 144.7  —d
2010, per 100,000 105.4 80.8 101.5  —d
Abbreviations: BRFSS, Behavioral Risk Factor Surveillance System; CDC WONDER, Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epi-
demiologic Research.
a Men aged 35 or older in 2010. The number for overall does not equal the total for whites and blacks because that number includes all men in the state, irrespect-
ive of race/ethnicity.
b Values for smoking status are weighted percentages (incorporating sampling weights) for 1999 and 2010.
c Total deaths from select causes from 1999 to 2010
d Insufficient data for current smoking, prostate cancer mortality rates, and mortality from external causes for black men in Utah (≤20 participants for current
smoking or ≤20 deaths for mortality outcomes for all years).
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Table 2. Average Annual Percentage Change (AAPC)a in Current Smoking and Mortality Rates for Prostate Cancer and External
Causes Among Men Aged 35 Years or Older in 4 States, by State and Race, BRFSS, 1999–2010, and CDC WONDER, 1999–2010
Characteristicb California, AAPC (95% CI) Kentucky, AAPC (95% CI) Maryland, AAPC (95% CI) Utah, AAPC (95% CI)c
Overall
Current smoker −3.5 (−4.4 to −2.5) −3.0 (−4.0 to −1.9) −3.0 (−7.0 to 1.2) −3.5 (−5.6 to −1.3)
Prostate cancer −2.5 (−2.9 to −2.2) −3.5 (−4.3 to −2.7) −3.5 (−4.1 to −3.0) −2.1 (−3.8 to −0.4)
Mortality from external causes 0.8 (−0.3 to 1.9) 1.8 (1.0 to 2.5) −0.4 (−1.8 to 1.1) 0.5 (−0.1 to 1.2)
Non-Hispanic white men
Current smoker −4.0 (−5.2 to −2.9) −3.4 (−4.7 to −2.1) −3.9 (−5.2 to −2.7) −3.8 (−5.9 to −1.7)
Prostate cancer mortality rates −2.4 (−2.8 to −1.9) −3.4 (−4.4 to −2.4) −3.7 (−4.6 to −2.9) −1.8 (−3.5 to 0)
Mortality from external causes 2.1 (1.0 to 3.2) 2.1 (1.3 to 3.0) 1.3 (0.4 to 2.2) 1.1 (0.3 to 1.8)
Non-Hispanic black men
Current smoker −1.8 (−4.9 to 1.4) 0.7 (−3.5 to 5.0) −5.0 (−7.4 to −2.6)  —
Prostate cancer mortality rates −2.7 (−4.1 to −1.2) −2.8 (−5.9 to 0.4) −4.0 (−5.4 to −2.6)  —
Mortality from external causes −0.6 (−4.3 to 3.4) −2.5 (−4.7 to −0.3) −2.0 (−3.2 to −0.7)  —
Abbreviations: AAPC, average annual percentage change; BRFSS, Behavioral Risk Factor Surveillance System; CDC WONDER, Centers for Disease Control and Pre-
vention’s Wide-Ranging Online Data for Epidemiologic Research; CI, confidence interval.
a Based on weighted prevalence (for current smoking) or mortality rates age adjusted to the 2000 US standard million population (for prostate cancer mortality
rates and mortality from external causes) from 1999 through 2010, analyzed by the Joinpoint Regression Program, version 4.1.0 (National Cancer Institute), allow-
ing up to 2 joinpoints.
b Data on smoking are from BRFSS 1999–2010 (10); data on mortality rates are from CDC WONDER (11).
c Insufficient data for current smoking, prostate cancer mortality rates, and mortality from external causes for black men in Utah (≤20 participants for current
smoking or ≤20 deaths for mortality outcomes for all years).
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